Summary In a previous study using RNA in 
Prostate cancer is the most common malignancy among males (Boring et al., 1994) . Preventive screening programmes reveal more organ-confined lesions, leading to an increase in the number of radical prostatectomies. However, this may not have a significant impact on overall survival as these tumours show a variable clinical course that cannot be predicted with the current available markers. Thus, patients with the same disease status may or may not progress (Johansson et al., 1989; Adolfsson et al., 1990; Bostwick et al., 1993) after radical prostatectomy. As cancer cells undergo aberrant patterns of differentiation, it is likely that their phenotype, including cellular components responsible for differentiation, might be modified. Several biological markers have been studied in prostate cancer, but their prognostic value is unknown. Some markers have been found to be associated with the onset of prostatic cancer, i.e. increased Sphase and elevated transforming growth factor (TGF)-/3, (Nagle et al., 1991) . Other investigators have shown a correlation between the high expression of Ki-67, proliferating cell nuclear antigen (PCNA), MIB-1, and recurrent or metastatic disease (Bostwick et al., 1992; Skalova et al., 1994) . We and others have shown that loss of E-cadherin, a molecule involved in maintaining tissue integrity, is associated with progression in prostate cancer (Umbas et al., 1992 (Umbas et al., , 1994 al., 1988, 1989) and the closely related HMGI-C (Manfioletti et al., 1991) . Members of the HMG-I(Y) family are distinguished from other groups of HMG proteins by their ability to specifically bind to the minor groove of A: T-rich DNA sequences (Elton et al., 1986; Solomon et al., 1986) , presumably similar to antitumour and antiviral drugs (netropsin, distamicin) and the dye Hoechst 33258 (Disney et al., 1989; Wegner et al., 1990 ).
In addition to its involvement in chromosome condensation (Yang-yen et al., 1988; Giancotti et al., 1989) , recent reports suggested another possible role of HMG-I(Y) as a transcription regulatory factor (Fashena et al., 1992; Skalnik et al., 1993) . Moreover, the cell cycle-dependent p34CdC2 like kinases phosphorylate the DNA-binding domains of HMG-I(Y) both in vitro and in vivo (Meijer et al., 1991) , which may serve as an important regulatory mechanism for DNA-binding modulation (Disney et al., 1989) . A striking correlation between elevated levels of HMG-I(Y) and both neoplastic cell transformation (Giancotti et al., 1987; Johnson et al., 1988) and metastases (Bussemakers et al., 1991; Ram et al., 1993) KaplanMeier (Kaplan et al., 1958) , and the differences between groups were performed using the log-rank test. (Figure 1, a-d (Figure 1, i-l) . Table II summarises our statistical analysis. Statistically significant differences in HMG-I(Y) expression levels between all groups were found (see t and P-values in Table II ). The analysis indicated that HMG-I(Y) expression increased with Gleason grade (see Figure 2) . Considering that increased expression of HMG-I(Y) might be associated with aggressiveness and invasiveness of tumours, we evaluated whether HMG-I(Y) expression (over the fixed threshold of 0.65) correlated with clinical stage. High HMG-I(Y) expression (A>0.65) was associated with high-stage disease, i.e. 25% in T1+T2 vs 91% in T3 and T4 (chi-square= 15.8, P=0.001, see Table III) .
PSA levels and HMG-I(Y) expression correlation
In order to assess whether the disease had already spread outside the prostate after radical prostatectomy in those cases of high Gleason grade, we compared patient levels of PSA with the expression levels of HMG-I(Y). PSA was measured periodically (once per 6 months) during the follow-up of the (Figure 3 log-rank test: chi-square = 5.0175, P= 0.025). Increased HMG-I(Y) mRNA levels are often found in rapidly proliferating or undifferentiated cells and in various malignant tissues including prostate cancer (Lund et al., 1983; Elton et al., 1986; Johnson et al., 1988; Bussemakers et al., 1991) . Furthermore, induction of differentiation results in the down-regulation of HMG-I(Y) mRNA expression, suggesting that HMG-I(Y) expression is associated with cellular differentiation (Vartianen et al., 1988) . In a previous study we showed that in specimens of non-malignant prostate tissue, HMG-I(Y) expression was absent, whereas HMG-I(Y) expression was clearly detectable in prostate cancer cells (Tamimi et al., 1993) . Moreover, a statistically significant correlation between the level of HMG-I(Y) expression and Gleason grade and stage was found (Tamimi et al., 1993) . The present data on archival specimens confirm our previous findings (Figure 2 ) and corroborate the hypothesis that HMG-I(Y) expression is related to differentiation. Indeed, in well-differentiated tumours 2 of 14 cases (14%) showed low HMG-I(Y) expression, whereas 83% (19 of 23) of moderately differentiated and 97% (34 of 35) of poorly differentiated tumours showed high HMG-I(Y) expression (chisquare=38.78, P<0.0001). This strong correlation between tumour grade and HMG-I(Y) expression, determined by RISH, suggests that this might be used as an additional prognostic indicator for prostate cancer. However, a multivariate regression analysis, which included Gleason grade, tumour stage, HMG-I(Y) expression and PSA levels showed Gleason grade as the most accurate predictor of progression (chi-square=21.35, P<0.0001). In this study, high HMG-I(Y) levels as measured by RISH were indicative of a worse prognosis, although additional value over the more subjective grading methods was not evident.
We found that HMG-I(Y), as measured with image analysis, was highly expressed in 14 of 27 cases of tumours (51%) that were organ confined (TI -2) in contrast to 41 of 45 tumour cases (91%) invading through the prostate capsule (T3 -4). Thus, there seems to be a trend towards higher HMG-I(Y) levels in higher stage tumours, which might be a HMG-I(Y) has been implicated in a number of functions: the subunits of NF-KB (p50 and p65), members of the oncogene rel family, can only activate transcription from their binding site PRDII when HMG-I(Y) is also bound (Thanos et al., 1992) , similarly the E-selectin gene, encoding for endothelial cell adhesion proteins, can be activated only via interleukin (IL)-13 and tumour necrosis factor (TNF)-cx induction of NF-KB through HMG-I(Y) binding (Lewis et al., 1994) . HMG-I(Y) is involved in rescuing scaffoldassociated regions (SARs) and A:T rich sequences from histone HI-mediated repression, which fold the chromatin fibre into higher order structures (Zhao et al., 1993) ; finally HMG-I(Y) plays a role in the suppression of IL-4 transcription in T lymphocytes (Chuvpilo et al., 1993) , as well as in the stimulation of a specific isoform of the activating transcription factor 2 (ATF-2195) binding to interferon ,B (IFN-fl) (Du et al., 1994) . In view of the multifunctionality of HMG-I(Y) in mammalian cells, it is not Correlation between stage and HMG-I(Y) expression over and below a threshold of 0.65 (normalised score A). 
